AC Immune SA (ACIU) News

AC Immune SA (ACIU): $2.40

0.06 (+2.56%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ACIU News Items

ACIU News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACIU News Highlights

  • For ACIU, its 30 day story count is now at 4.
  • Over the past 22 days, the trend for ACIU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AC, SA and PET are the most mentioned tickers in articles about ACIU.

Latest ACIU News From Around the Web

Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trialPI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated TauTau accumulation, a key Alzheimer's disease pathology, correlates with cognitive impairment Lausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharm

Yahoo | January 18, 2023

AC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29%

A look at the shareholders of AC Immune SA ( NASDAQ:ACIU ) can tell us which group is most powerful. With 39% stake...

Yahoo | January 7, 2023

How should investors view AC Immune SA (ACIU)?

AC Immune SA (NASDAQ:ACIU) marked $2.13 per share on Thursday, down from a previous closing price of $2.18. While AC Immune SA has underperformed by -2.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACIU fell by -57.65%, with highs and lows ranging from $5.12 to […]

US Post News | January 6, 2023

A Full Position In AC Immune To My Tax Loss Selling Basket (ACIU)

AC Immune recently fell due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand. Read why I have a full position in ACIU.

Seeking Alpha | December 27, 2022

Boom Or Bust: What Does The Future Hold For AC Immune SA (NASDAQ: ACIU) Stock?

AC Immune SA (NASDAQ:ACIU)’s traded shares stood at 1.88 million during the last session, with the company’s beta value hitting 0.56. At the close of trading, the stock’s price was $1.79, to imply an increase of 2.87% or $0.05 in intraday trading. The ACIU share’s 52-week high remains $5.40, putting it -201.68% down since that … Boom Or Bust: What Does The Future Hold For AC Immune SA (NASDAQ: ACIU) Stock? Read More »

Marketing Sentinel | December 22, 2022

AC Immune SA (NASDAQ:ACIU) Has Made The -3.09% Recovery, Could Gain Another -178.35% Ahead

In last trading session, AC Immune SA (NASDAQ:ACIU) saw 0.61 million shares changing hands with its beta currently measuring 0.52. Company’s recent per share price level of $1.94 trading at -$0.1 or -4.90% at ring of the bell on the day assigns it a market valuation of $161.41M. That closing price of ACIU’s stock is … AC Immune SA (NASDAQ:ACIU) Has Made The -3.09% Recovery, Could Gain Another -178.35% Ahead Read More »

Marketing Sentinel | December 17, 2022

AC Immune Could Reload On Upcoming Readout

AC Immune has a lot of cash. Their lead vaccine was selected by a Big Pharma partner for later-stage development. See our analysis of ACIU stock here.

Seeking Alpha | December 6, 2022

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

AC Immune ’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 S elect ed for Further Development

GlobeNewswire | November 30, 2022

AC Immune SA: AC Immune''s Alzheimer''s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

AC Immune''s Alzheimer''s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased…

Finanz Nachrichten | November 30, 2022

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | November 25, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5758 seconds.